|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The findings of our study provide the basis for further development of 5-thiohistidines as therapeutics for GGT-positive tumors and highlight that GGT inhibition is involved in autophagy.
|
31375562 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, our results provide new insight for further development of 5-thiohistidine derivatives as therapeutics for GGT-positive tumors.
|
31757046 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the upregulation of TROAP was associated with increased serum AFP and GGT; the greater the tumor number was, the larger the tumor size, differentiation grade, and cancer embolus in clinical analysis.
|
30854102 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we report a strategy of combining an α<sub>v</sub>β<sub>3</sub>-integrin-receptor-targetable ligand, c-RGD, with the γ-glutamyl transpeptidase (GGT)-recognizable substrate, γ-glutamate (γ-Glu), to develop a tumor-targeting and GGT-activatable near-infrared (NIR)-fluorescent probe for the noninvasive imaging of tumors in living mice.
|
29376641 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CSCs-exosomes induced a significant increase in liver relative weight and serum levels of cancer markers (AFP and GGT) and liver enzymes (ALT, AST, and ALP), intensive immunostaining for the HCC marker GST-P, and an increased number and area of tumor nodules as compared to HCC rats injected by PBS.
|
30224923 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
No significant relationship between Wls expression and liver cirrhosis, ALT, GGT, age, sex, or tumor focality was found.
|
29127606 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, ALP is correlated to γ-glutamyl transpeptidase (GGT; p = 0.002) and the tumor location in the liver (p = 0.007), and increased levels of ALP had poor effects on overall survival (p = 0.006) and progression-free survival (p = 0.022).
|
29548922 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The multivariable Cox analysis shows that the hazard ratio of overall survival for high tumor GGT is 1.69 (95% CI 1.19-2.37).
|
28404903 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Univariate analysis showed that preoperative TNM staging (P = .01), serum gamma-glutamyl transpeptidase (GGT) level (P = .03), vascular invasion (P = .00), and density of CD3+T (CT) (P = 0.01) were correlated significantly with disease-free survival (DFS); serum alpha-fetoprotein (AFP) level (P = .02), tumor size (P = .00), serum cholinesterase (CHE) (P = .04), and GGT level (P = .01), density of CD3+T(CT) (P = .00), CD8+T(CT)(P = .00), CD45RO+T(CT) (P = .00), and CD45RO+T (IM) (P = .02) were correlated with overall survival (OS).
|
28445292 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Due to the discordant results (GGT->GTT exon 2 KRAS mutation in the primary tumor, and KRAS-WT in the liver metastases), mutational analysis on liver metastasis was repeated using next-generation sequencing and enriching the sample in tumor cells by manual microdissection; the same type of mutation of the primary tumor (GGT->GTT exon 2 KRAS gene) was confirmed.
|
28665451 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gender (P = 0.046), cigarette smoking (P = 0.007), serum AFP level (P = 0.001), GGT level (P = 0.002), maximum size of tumors (P = 0.009), liver cirrhosis (P = 0.025), portal vein tumor thrombus (P = 0.022), microvascular tumor thrombus (P = 0.007) and TNM Stage (P = 0.001) were significantly affected DFS.
|
26577107 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found metastasis, gamma-glutamyl transpeptidase (GGT) and tumor node metastasis (TNM) stage were significantly different among patients with different CIMP status.
|
19879258 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sequence analysis of tumor DNA revealed that GGT (Gly) was replaced by GAT (Asp; 35%), GTT (Val; 32%), AGT (Ser; 13%), GCT (Ala; 10%), TGT (Cys; 8%), and CGT (Arg; 2%) for codon 12, and by GAC (Asp) as the only type of mutation for codon 13.
|
14760087 |
2004 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PCR single-strand conformation polymorphism and subsequent DNA sequencing analysis showed two nucleotide substitutions resulting in Trp736stop (TGG to TGA) and Gly737Ser (GGT to AGT) in one tumor specimen.
|
11844605 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Total GGT activities in patients with liver diseases and extrahepatic tumors were abnormally increased.
|
10679644 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The GGT-positive tumors were significantly more resistant to the toxicity of cisplatin than the GGT-negative tumors.
|
10223181 |
1999 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations of Ki-ras codon 12 (wild type = GGT = glycine) or codon 13 (wild type = GGC = glycine) were detected in 37.7% of the tumors; 80.8% (584 of 723) of all the specified mutations occurred in codon 12, and 78.1% (565 of 723) of all the specified mutations were at the second base of either codon.
|
9586664 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A summary of its expression in neoplastic tissues and the ways in which GGT effects the response of tumors to chemotherapy follows.
|
9679564 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The same K-ras point mutation (substitution of GAT for GGT) was detected in both the blood and the primary tumor in a Dukes' C patient.
|
9001346 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Out of three PW samples, two showed mutation at the second position from GGT to GAT similar to their PB and tumor samples.
|
12118546 |
1996 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The mutation from GGT (glycine) to GAT (aspartic acid) was the most frequent mutation in the tumor xenografts (64.7%, 11/17) as well as in the primary human neoplasms (64.7%, 11/17).
|
7872685 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
First, we found that the overall prevalence of mutations within codons 12 and 13 of the K-ras gene was 25% in the nonrecurring group vs. 71% in the patients with recurrent disease (P < 0.0001) and, second, that mutations other than GGT to GAT occurred, with one exception, exclusively in recurring tumors.
|
8462792 |
1993 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The original primary tumor and two metastatic lymph nodes were previously found to have 50-fold amplification of c-myc and also 3- to 6-fold amplification of activated c-Ki-ras with a point mutation from GGT to CGT at codon 12.
|
3778442 |
1986 |